Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 58

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 58
---
Note: From Q4 FY2024, rusfertide is part of the Oncology portfolio.

Our oncology pipeline in clinical development as of May 8, 2025 (the date of our annual earnings release), along with notes for major subsequent developments thereafter, is as follows:

  Development code                      Type of Drug                                                     Modality                     Indications / additional formulations                                                                                                              Country/Region      Stage                
  TAK-113 1                             VEGFR inhibitor (oral)                                           Small molecule               Previously treated metastatic Colorectal Cancer (mCRC)                                                                                             EU                  Approved (Jun 2024)  
                                                                                                                                      Treatment of unresectable advanced or recurrent Colorectal Cancer (CRC) that has progressed after chemotherapy                                     Japan               Approved (Sep 2024)  
  SGN-35 2                              CD30 monoclonal antibody-drug conjugate (injection)              Biologic and other           Front line Hodgkin’s lymphoma – BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) 3      EU                  Filed (Apr 2024) 4   
  TAK-121 5                             Hepcidin mimetic peptide (injection)                             Peptide/oligonucleotide      Polycythemia vera                                                                                                                                  U. S.               P-III                
  TAK-226 6                             Activin A and B inhibitor                                        Biologic and other           2L anemia-associated Myelodysplastic Syndrome                                                                                                      U. S.               P-III 7              
                                                                                                                                      Anemia-associated Myelofibrosis                                                                                                                    -                   P-II                 
  TAK-853 8                             Antibody-drug conjugate targeting folate receptor α (FRα)        Biologic and other           Platinum-sensitive ovarian cancer                                                                                                                  Japan               P-III                
                                                                                                                                      Platinum-resistant ovarian cancer                                                                                                                  Japan               P-II                 
  TAK-012                               Variable delta 1 (Vδ1) gamma delta (γδ) T cells (injection)      Cell therapy                 Relapsed/refractory Acute Myeloid Leukemia                                                                                                         -                   P-I                  

____________

Notes:

(1) Partnership with HUTCHMED

(2) Partnership with Pfizer Inc.

(3) Submission based on data from German Hodgkin Study Group HD21 trial.

(4) In June 2025, T